Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ulcerative Colitis (Disorder) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Ulcerative Colitis (Disorder). Eligibility criteria explained in plain English.

TrialFinderData lists 4 Ulcerative Colitis (Disorder) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Benethera (Shaoxing) Biotechnology Co., Ltd. (1), Humanitas Clinical and Research Center (1), Showa Inan General Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is BDHK-2009 Tablets (drug, 1 trial), followed by Placebo, Vedolizumab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Ulcerative Colitis (Disorder) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT07632573

A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult

A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part...

Sponsor: Benethera (Shaoxing) Biotechnology Co., Ltd.Enrolling: 681 location
RECRUITINGNCT06691061

The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed...

Sponsor: Humanitas Clinical and Research CenterEnrolling: 4501 location
RECRUITINGNCT07243639

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course,...

Sponsor: Showa Inan General HospitalEnrolling: 301 location
RECRUITINGNCT07115862

Effects of Pomegranate Juice on Ulcerative Colitis

The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will: 1. lower inflammation (in the gut as well as generally in the...

Sponsor: University of California, Los AngelesEnrolling: 302 locations

Frequently Asked Questions

There are currently 4 clinical trials for Ulcerative Colitis (Disorder), with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ulcerative Colitis (Disorder), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Ulcerative Colitis (Disorder), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.